In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Foamix Pharmaceuticals Ltd.

www.foamix.com

Latest From Foamix Pharmaceuticals Ltd.

Bookmark
  • News

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

By Bridget Silverman

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters
Bookmark
  • News

Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label

By Mandy Jackson

Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.

Financing Business Strategies
Bookmark
  • News

Keeping Track: US FDA Receives Submissions Galore As Year Ends

By Bridget Silverman
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
Drug Review Regulation
Bookmark
  • News

Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition

By Emily Hayes

Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical minocycline foam on its own.

 

Research & Development Dermatology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
      • Transdermal
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Foamix Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Foamix Pharmaceuticals Ltd.
  • Senior Management
  • David Domzalski, CEO
    Ilan Hadar, CFO
    Matt Wiley, Chief Commercial Officer
    Russell Elliott, PhD, SVP, Pharmaceutical Dev.
    Iain Stuart, PhD, CSO
    Deepa Desai, VP, Reg. Affairs
  • Contact Info
  • Foamix Pharmaceuticals Ltd.
    Phone: (972) 8 9316233
    Weizmann Science Park
    2 Holzman St.
    Rehovot, 7670402
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By